Tag: biomimics 3d
“Excellent” three-year results presented for the BioMimics 3D stent in longer...
At the 2022 Vascular Interventional Advances (VIVA) meeting (31 October–3 November, Las Vegas, USA), Michael Lichtenberg (Arnsberg Clinic, Arnsberg, Germany) reported a subgroup analysis...
Three-year results of Veryan Medical’s MIMICS-3D EU study revealed at ISET...
Veryan Medical has confirmed the release of MIMICS-3D EU three-year results by the study principal investigator Michael Lichtenberg (Vascular Center Arnsberg, Klinikum Hochsauerland, Arnsberg,...
First patient enrolled in MIMICS-3 USA study
Veryan Medical recently announced that the first patient has been enrolled in the MIMICS-3 USA study by John H Rundback at NJ Endovascular &...
Veryan Medical announces US launch and first commercial implant of BioMimics...
Veryan Medical recently announced the US launch and first commercial implant in the USA of the BioMimics 3D vascular stent system.
According to a press...
VIVA 2019: One-year freedom from clinically-driven target lesion revascularisation in MIMICS-3D...
One-year results of the MIMICS-3D study were announced today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA). Freedom from...
BioMimics 3D stent receives US FDA premarket approval
UK-based Veryan Medical has announced that the company has received premarket approval (PMA) for their BioMimics 3D vascular stent system from the US Food...
MIMICS-3D registry completes enrolment
Veryan Medical has announced completion of enrolment of the 500th patient in the MIMICS-3D pan-European registry, a prospective, multicentre, observational registry to evaluate the...
The value of Swirling Flow and the BioMimics 3D clinical study...
This article is an advertorial by Veryan Medical.
Authors: PA Gaines, T Sullivan, G Ansel, C Caro
Introduction
Medical advances in the treatment of femoropopliteal artery disease...
MIMICS-2 shows 90% freedom from target lesion revascularisation at one year...
The BioMimics 3D (Veryan Medical) helical swirling flow stent system provides an alternative to antiproliferative drugs, according to one-year data from the MIMICS-2 trial....
New Mimics data support use of the BioMimics 3D swirling flow...
New significant outcomes from the Mimics study have been presented at the 15th annual conference on Vascular Interventional Advances (VIVA; 11-14 September, Las Vegas,...
Veryan Medical receives £13.5m further funding
Veryan Medical has received a further £13.5m of funding in the form of both equity and debt from its existing investors, including Touchstone Innovations,...
